# A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

> **NCT06559176** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Prime Medicine, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Chronic Granulomatous Disease
- Granulomatous Disease, Chronic

## Interventions

- **BIOLOGICAL:** PM359

## Key facts

- **NCT ID:** NCT06559176
- **Lead sponsor:** Prime Medicine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-10-17
- **Primary completion:** 2030-01
- **Final completion:** 2030-02
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06559176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06559176, "A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06559176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*